

BEYOND THE SKIN



Managing eye disorders in severe atopic dermatitis



Reference list for ADVENT Interactive Clinical Tutorial held on 18th May 2023

1. Achten RE, et al. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis. *Acta Derm Venereol.* 2022;102:adv00666. PMID: [35098318](#)
2. Akinlade B, et al. Conjunctivitis in dupilumab clinical trials. *Br J Dermatol.* 2019;181:459–473 PMID: [30851191](#)
3. Ariëns LF, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. *JAAD.* 2021;84:1000–1009. PMID: [32946967](#)
4. Bachert C et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet* 2019. 394:1638-1650. PMID: [31543428](#)
5. Bakker DS, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. *Br J Dermatol.* 2019;180:1248–1249. PMID: [30597515](#)
6. Beck KM, et al. Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases. *Am J Clin Dermatol.* 2019;20:797–805. PMID: [31359350](#)
7. Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. *Immunol Allergy Clin North Am.* 2010;30:323–336. PMID: [20670816](#)
8. Dupixent (Dupilumab) Australian Product Information. June 2022. [Click to access.](#)
9. Foley P, et al. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. *Australas J Dermatol.* 2022;63:421–436. PMID: [36125089](#)
10. Gooderham M, et al. Diagnosis and Management of Conjunctivitis for the Dermatologist. *J Cutan Med Surg.* 2018;22:200–206. PMID: [29191053](#)
11. Mennini M, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med.* 2017;376:1090. PMID: [28301105](#)
12. Nettis E, et al. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. *J Invest Allergol Clin Immunol.* 2022;32(2):124–132. PMID: [32856595](#)
13. Paller AS, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol.* 2020;83(5):1282-93. PMID: [32574587](#)
14. Shen E, et al. Dupilumab-Induced Follicular Conjunctivitis. *Ocul Immunol Inflamm.* 2018;27(8):1339–1341. PMID: [30335586](#)
15. Simpson EL, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. *JAMA Dermatol.* 2020;156:44–56. PMID: [31693077](#)
16. Thyssen JP, et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. *J Am Acad Dermatol.* 2017;77:280–286.e1. PMID: [28601391](#)
17. Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with *Demodex* and increased interleukin-17 levels? *Br J Dermatol.* 2018;178:1220. PMID: [29333603](#)
18. Uchio E, et al. Systemic and local immunological features of atopic dermatitis patients with ocular complications. *Br J Ophthalmol.* 1998;82:82–87. PMID: [9536888](#)
19. Weyne J, et al. Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. *Dermatol Ther (Heidelb).* 2020;10(6):1415–1421. PMID: [33047298](#)